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Abstract: Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both
gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies
and solid tumours, suggesting a complex, context-dependent role of this methyltransferase.
The successful implementation of molecularly targeted therapies against EZH2 requires a greater
understanding of the potential mechanisms by which EZH2 contributes to cancer. One aspect of this
effort is the mapping of EZH2 partner proteins and cellular targets. To this end we performed
affinity-purification mass spectrometry in the FAB-M2 HL-60 acute myeloid leukaemia (AML) cell
line before and after all-trans retinoic acid-induced differentiation. These studies identified new
EZH2 interaction partners and potential non-histone substrates for EZH2-mediated methylation.
Our results suggest that EZH2 is involved in the regulation of translation through interactions with
a number of RNA binding proteins and by methylating key components of protein synthesis such as
eEF1A1. Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is
highly expressed in many human tumours, these findings present new possibilities for the therapeutic
targeting of EZH2 in AML.
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1. Introduction
Acute myeloid leukaemia (AML) is the most commonly occurring acute haematological
malignancy in adults, representing more than 80% of all leukaemias in patients over 60 years of age [1].
AML also accounts for 15–20% of childhood leukaemia cases, making it the second most common acute
leukaemia in children [2–4]. Despite advances in diagnosis, stratification and treatment, the disease
remains largely incurable (in 60–65% of patients <60 years and 85–95% of patients >60 years [5]),
and overall 5-year survival rates remain poor at only 25% [4,6]. Furthermore, treatment outcomes for
relapsed patients are low, with complete remission rates under 25% [7,8]. New treatment options are
therefore urgently required.
Epigenetic events play a central role in normal development and differentiation, and it is
unsurprising that mutation and/or deregulation of DNA and histone modifiers is a frequent event
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in cancer [9]. Epigenetic enzymes that have been implicated in the promotion of haematological
malignancies include MLL, translocations of which occur in approximately 80% of infant leukaemias
and 5–10% of adult AML [10], resulting in gain-of-function mutations of the encoded H3K4
methyltransferase. Other recently described examples include mutation of DNMT3A (which occurs in
approximately 20% of AML patients) [11], aberrant expression of the LSD1 (KDM1A) demethylase
(which is strongly implicated in AML) [12–14], and overexpression of histone deacetylase 9 (HDAC9),
which is associated with leukaemia and lymphoma [15,16]. Perhaps the most widely-studied epigenetic
modifiers, however, are the Polycomb group of proteins (PcG), which form two distinct multiprotein
repressive complexes, PRC1 and PRC2. PRC1 is required for the ubiquitination of histone H2A lysine
119, which proceeds via Ring1a or Ring1b E3 ligases. The core PRC1 subunit BMI1 (also known as
PCGF4 or RNF51) is required for cancer stem cell maintenance [17] and its overexpression has been
implicated in leukaemia and lymphoma. The canonical function of PRC2 is to catalyse the methylation
of histone H3 lysine 27 (H3K27) and contains either the EZH1 or EZH2 methyltransferases. EZH2 has
been the subject of intense research in recent years due to its role in a wide range of cancers and to its
potential as a therapeutic target [18].
In addition to being overexpressed in a number of solid tumours, EZH2 is also frequently mutated
in haematological malignancies. In contrast to the selection for activating point mutations (Y641
and A677) in the SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) domain of EZH2
described in B-cell malignancies [19–21], a range of loss-of-function aberrations (including in other
PRC2 members) have been found in 25% of T-cell acute lymphoblastic leukaemia (ALL) cases,
3% of primary AML, 29% of secondary AML, and 15% of myeloproliferative disorders [22–24].
Importantly, all these perturbations have been shown to lead to poor prognosis and diminished
overall survival [23,25,26]. In addition to mutation of EZH2 in AML, evidence strongly suggests its
aberrant expression can promote self-renewal of leukaemic stem cells and block differentiation [27–29].
Deregulation of EZH2/PRC2 function can therefore occur in a number of ways, pointing to a complex
role that may be dependent on the cell type and on the stage of hematopoietic development at which
mutations or deregulation of expression occur.
In order to improve both our understanding of the dynamic functions of EZH2 as well as its
potential as a therapeutic target, it is important to identify proteins that interact with the core PRC2
complex, as well as non-histone enzymatic substrates. Here, it is important to note that none of the four
core PRC2 components (EZH2, SUZ12, EED, and AEBP1/2) has a DNA binding domain and that
the PRC2 complex depends on factors such as JARID2, YY1, or AEBP2 [30], and/or non-coding RNAs
such as XIST and HOTAIR to be recruited to specific loci [31]. Non-canonical EZH2-containing PRC2
activities identified thus far have included scaffold functions and lysine modifications of non-histone
proteins, including EZH2 bridging of β-catenin and TCF7 (formerly named Tcf1, T cell factor 1) [32],
interaction with RelA and RelB [33], methylation of androgen receptor [34], as well as interactions with
STAT3 [35,36], GATA4 [37], RORα [38], and Talin1 [39]. Therefore, using the well-characterised
HL-60 cell line as a model system [40], we performed mass spectrometry (MS) as an unbiased
approach to quantitatively investigate potential modulators (recruiters or co-repressors) and enzymatic
targets of EZH2 in the context of AML. We additionally investigated whether these interactions were
modulated in response to all-trans retinoic acid (AtRA)-induced myeloid differentiation.
2. Results
We performed five separate MS experiments that comprised a total of five IgG controls and
seven EZH2 immunoprecipitations (IP), and one IP with an antibody raised against pan-methyl lysine.
Good peptide coverage of EZH2 was achieved in the MS runs (going up to 50% coverage based
on peptide assignment of at least 95% peptide threshold using the Peptide Prophet algorithm [41])
and all core components of the PRC2 complex were found to be significantly enriched (highlighted
in blue) (Figure 1).
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Figure 1. Affinity-purification mass spectrometry coverage of EZH2 and enrichment of PRC2 member 
proteins. (A) Sequence coverage of EZH2 (detected peptides are highlighted in yellow and amino 
acids with post-translational modifications are shown in green) from a representative mass 
spectrometry run (peptide threshold 95%); (B) Scatter plot of hits from all five mass spectrometry 
experiments passing a 2-fold change cut-off showing enrichment of core PRC2 components (shown 
in blue). 
2.1. The EZH2 Interactome in HL-60 Cells 
The first part of this study focussed on building the first EZH2 interactome in AML cells and on 
quantifying potential changes upon short (overnight) stimulation with AtRA. For this analysis, we 
considered all seven EZH2 IP and compared the protein abundance to the one found in all five IgG 
IP (a stringent 2-fold change cut-off was applied in this case) identifying 181 proteins interacting with 
EZH2. After further filtering (CRAPome [42] and SAINTexpress [43]) and comparison to recently 
published PcG complexome data [44] (Figure S1), we identified 143 proteins that co-IP with EZH2 in 
AML cells at high confidence (>0.8 SAINTexpress score). In order to highlight potential molecular 
complexes among the EZH2 interactors, clustering analysis was then performed with the Cluster 
maker [45] (MCL cluster), MCODE [46], and ClusterONE [47] plugins in Cytoscape [48], showing one 
main cluster of proteins and two smaller ones (Figures 2 and S2). 
Figure 1. Affinity-purification mass spectrometry coverage of EZH2 and enrichment of PRC2 member
proteins. (A) Sequence coverage of EZH2 (detected peptides are highlighted in yellow and amino acids
with post-translational modifications are shown in green) from a representative mass spectrometry run
(peptide threshold 95%); (B) Scatter plot of hits from all five mass spectrometry experiments passing
a 2-fold change cut-off showing enrichment of core PRC2 components (shown in blue).
2.1. The EZH2 Interactome in HL-60 Cells
The first part of this study focussed on building the first EZH2 interactome in AML cells and
on quantifying potential changes upon short (overnight) stimulation with AtRA. For this analysis,
we considered all seven EZH2 IP and compared the protein abundance to the one found in all five
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Figure 2. The EZH2 interactome in HL-60 acute myeloid leukaemia (AML) cells. (A) Network analysis 
of EZH2 interactome (2-fold change over IgG and 0.8 SAINTexpress score) showing related groups 
of proteins as clustered by Cytoscape (Makarov Clustering Algorithm in clusterMaker). Groups of 
PRC2 interacting proteins (third node from the left), as well as for RNA binding proteins involved in 
translation and splicing (first and second nodes on the top) can be distinguished; (B) MCODE clusters 
with protein symbols in each node confirming strong enrichment for RNA binding proteins (cluster 
1) and known PRC2 associated members (cluster 2). 
Further gene ontology (GO) analysis of hits using BinGO [49], David [50], and STRING [51] 
revealed a strong enrichment for proteins involved in RNA processing (splicing, mRNA metabolic 
processes) and translation (ribosomal proteins) located in the biggest cluster and one of the two 
Figure 2. The EZH2 interactome in HL-60 acute myeloid leukaemia (AML) cells. (A) Network analysis
of EZH2 interactome (2-fold change over IgG and 0.8 SAINTexpress score) showing related groups
of proteins as clustered by Cytoscape (Makarov Clustering Algorithm in clusterMaker). Groups
of PRC2 interacting proteins (third node from the left), as well as for RNA binding proteins involved in
translation and splicing (first and second nodes on the top) can be distinguished; (B) MCODE clusters
with protein symbols in each node confirming strong enrichment for RNA binding proteins (cluster 1)
and known PRC2 associated me bers (cluster 2).
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Further gene ontology (GO) analysis of hits using BinGO [49], David [50], and STRING [51]
revealed a strong enrichment for proteins involved in RNA processing (splicing, mRNA metabolic
processes) and translation (ribosomal proteins) located in the biggest cluster and one of the two smaller
ones (Figure 3A). These results are in agreement with, and expand upon the most comprehensive
proteomics dataset on PcG proteins published to date [44]. Importantly, this analysis also identified
a major cluster of interacting proteins that are involved in gene expression and chromatin modifications
consisting primarily of PRC2 members (the second small cluster from Figure 2 and Figure S2B,C),
as well as several ribosomal proteins. Among those, there were several EZH2-recruiting proteins that
have not been previously demonstrated to interact with EZH2 in the context of AML, such as PHF1,
PHF19, LCOR, and EPOP (also known as C17orf96). Of note, several other proteins implicated in
transcriptional control were also identified including THOC4/ALYREF, DDX5, DMAP1, HNRNPK,
NONO, SFPQ, FLII, PARP1, PABP1, U2AFA, PTBP1, and YBX1 (Table 1).
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Figure 3. Gene ontology analysis of EZH2 interactome. (A) Gene ontology (Cytoscape–BinGO) 
showing significant enrichment for proteins involved in translation, RNA splicing, and gene 
expression. Node colour corresponds to p-value (see scale). Gene ontology analysis of EZH2 
interactome (cont.); (B) Quantitative network analysis of EZH2-interacting proteins changing their 
relative frequency of interaction upon differentiation. Blue-coloured proteins represent ones found to 
co-IP with EZH2 at higher frequency in untreated HL-60 cells, whereas pink-coloured “preys” were 
found enriched in cells treated with AtRA; (C) Gene ontology (GO) analysis of proteins that change 
their interaction frequency with EZH2 upon AtRA-driven myeloid differentiation suggesting 
involvement in RNA metabolism, splicing, and control of gene expression. 
  
Figure 3. Gene ontology analysis of EZH2 interactome. (A) Gene ontology (Cytoscape–BinGO)
showing significant enrichment for proteins involved in translation, RNA splicing, and gene expression.
Node colour corresponds to p-value (see scale). Gene ontology analysis of EZH2 interactome (cont.);
(B) Quantitative network analysis of EZH2-interacting proteins changing their relative frequency
of interaction upon differentiation. Blue-coloured proteins represent ones found to co-IP with EZH2 at
higher frequency in untreated HL-60 cells, whereas pink-coloured “preys” were found enriched in cells
treated with AtRA; (C) Gene ontology (GO) analysis of proteins that change their interaction frequency
with EZH2 upon AtRA-driven myeloid differentiation suggesting involvement in RNA metabolism,
splicing, and control of gene expression.
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Table 1. STRING gene ontology.
GO Category Description FDR Protein Name
GO.0006415 Translationaltermination 1.27 × 10
−43
RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL15, RPL17,
RPL18, RPL18A, RPL23, RPL24, RPL27A, RPL3, RPL35, RPL37A,
RPL4, RPL5, RPL6, RPL7, RPL8, RPL9, RPLP0, RPLP1, RPLP2,
RPS10, RPS12, RPS13, RPS15, RPS19, RPS2, RPS24, RPS27A,
RPS3A, RPS4X, RPS6, RPS8
GO.0006414 Translationalelongation 4.54 × 10
−42
RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL15, RPL17,
RPL18, RPL18A, RPL23, RPL24, RPL27A, RPL3, RPL35, RPL37A,
RPL4, RPL5, RPL6, RPL7, RPL8, RPL9, RPLP0, RPLP1, RPLP2,
RPS10, RPS12, RPS13, RPS15, RPS19, RPS2, RPS24, RPS27A,
RPS3A, RPS4X, RPS6, RPS8
GO.0006413 Translationalinitiation 7.98 × 10
−41
PABPC1, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL15,
RPL17, RPL18, RPL18A, RPL23, RPL24, RPL27A, RPL3, RPL35,
RPL37A, RPL4, RPL5, RPL6, RPL7, RPL8, RPL9, RPLP0, RPLP1,
RPLP2, RPS10, RPS12, RPS13, RPS15, RPS19, RPS2, RPS24,
RPS27A, RPS3A, RPS4X, RPS6, RPS8
GO.0010467 Geneexpression 2.09 × 10
−13
AEBP2, AICDA, ALYREF, ANPEP, CBX3, DAPK3, DDX5,
DMAP1, EED, EZH1, EZH2, FLII, FLNA, HNRNPF, HNRNPH1,
HNRNPK, IGF2BP1, JARID2, LCOR, LRRFIP1, MTF2, NOLC1,
NONO, PA2G4, PABPC1, PHF1, PHF19, RBBP4, RBBP7, RPL10,
RPL12, RPL13, RPL17, RPL18, RPL18A, RPL24, RPL27A, RPL3,
RPL35, RPL4, RPL5, RPL6, RPL7, RPL9, RPLP0, RPLP1, RPLP2,
RPS10, RPS12, RPS13, RPS19, RPS2, RPS24, RPS27A, RPS3A,
RPS6, RPS8, RRP1B, SFPQ, SND1, SRP14, SUZ12, U2AF2, YBX1
GO.0045892
Negative
regulation of
transcription
3.03 × 10−2
AEBP2, CBX3, DDX5, DMAP1, FLNA, HNRNPK, LCOR,
LRRFIP1, MTF2, NONO, PA2G4, PARP1, RBBP7, RPS27A, SFPQ,
SUZ12, YBX1
GO, gene ontology; FDR, false discovery rate.
2.2. Changes in the EZH2 Interactome in Response to AtRA
We next examined alterations to EZH2 interactions in response to myeloid differentiation.
Of the seven EZH2 IP mentioned above, four were of untreated HL-60 cells and three of HL-60 cells
stimulated with 0.1 µM AtRA. All runs were again merged and relative quantitation was performed
based on exclusive spectrum count. Initially, 82 proteins with a greater than 2-fold difference between
the conditions were identified, which were found to be at least 1.5 times more abundant in all 7
EZH2 IP versus all five IgG IP. Nevertheless, after filtering of the hits, 19 proteins were identified
as selectively interacting with EZH2 upon AtRA-induced differentiation (Table 2 and Figure 3B).
GO and network analyses (Figure 3C) showed strong enrichment for RNA binding proteins (13 out
of 19, FDR = 4.86 × 10−8), with a number of these hits being involved in mRNA splicing (HNRNPD,
HNRNPF, PABPC1, PTBP1, CCDC124) and transcription regulation (CBX3, HMGA, ILF3, MTDH).
Of note, none of the genes encoding these proteins were found to display changes in gene expression
in accordance with increased or decreased bait-prey interactions following 72 h of treatment with
AtRA (unpublished data). Assuming consistent protein stability, this suggests that the changes in
the EZH2 interactome identified here are unlikely to result from altered gene expression levels of any
of the preys identified.
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Table 2. STRING gene ontology for AtRA-regulated EZH2 interacting proteins.
GO Category Description FDR Protein Name
GO.0003723 RNAbinding 4.86 × 10
−8
ATP5A1, CCDC124, CORO1A, FLNA, HNRNPD,
HNRNPF, ILF3, MSN, MTDH, PABPC1, PTBP1,
RPSA, RRP1B
GO, gene ontology; FDR, false discovery rate.
2.3. Identification of Enzymatic Targets of EZH2
Finally, we sought to identify potential non-histone targets of EZH2 in AML. Four of the five
MS runs (six EZH2 IP and four IgG control IP) were re-run in order to detect methylated peptides.
Relatively few proteins modified by mono-, di-, or tri-methylation were detected (32 in total, 24 with
modified Lysine residues, eight with Arginine methylation). After filtering for proteins identified in
the EZH2 interactome (Figure 2), potential hits for lysine methylation identified with high confidence
(99.9% proteins threshold and 80–95% peptide threshold) included EZH2 itself (K735me1), SUZ12
(K4me1), CBX3 (K142me1), Histone H4 (K20me2), eEF1A1 (K55me2), and ADT2 (also known as SLC25A5)
(K51me3). (Tables 3 and 4, Figures 4 and S3).
Int. J. Mol. Sci. 2017, 18, 1440 9 of 16 
 
 
Figure 4. Structure of eEF1A1 and putative EZH2 methylation target site. (A) Ribbon structure view 
of mammalian eEF1A monomer showing close proximity of Lys 55 (highlighted in red) to the 
GTP/GDP (Guanosine-5'-tri/diphosphate) binding pocket (with a GDP molecule bound in the pocket); 
(B) Hydrophobicity surface view (hydrophobic, red; hydrophilic, blue; neutral, white) of eEF1A1 
showing that K55 is in a hydrophilic (blue colour) region close to GTP/GDP binding pocket that is 
potentially accessible for post-translational modifications and methylation by EZH2. 
Table 4. Summary of potential non-histone EZH2 enzymatic targets. 
Protein Name Gene Symbol Methylation Site Protein Function 
ADT2 (ADP/ATP Translocase 2) SLC25A5 K52me3 ADP/ATP mitochondrial translocase 
CBX3 (Chromobox 3) CBX3 K142me1 Heterochromatin binding 
eEF1A1 (Elongation factor 1-α1) EEF1A1 K55me2, K165me2 Regulation of elongation 
EZH2 (Enhancer of zeste 
homology 2) 
EZH2 K735me1 Protein lysine methyltransferase 
SUZ12 (Polycomb Repressive 
Complex 2 Subunit) 
SUZ12 K4me1 
Regulation of H3K27 methylation 
and gene expression 
ALYREF (Aly/REF Export 
Factor) 
ALYREF K4me3 
Chaperone of basic-region leucine 
zipper (bZIP) proteins 
3. Discussion 
In this study, we sought to enhance our understanding of the complex biological roles of the 
PRC2 complex in AML by analysing the EZH2 interactome (Figure 5). We found that previously 
established interactions with PRC2-recruiting proteins such as PHF1, PHF19, LCOR, JARID2, and 
EPOP are conserved in HL-60 cells and identified several proteins involved in transcriptional 
regulation including ALYREF, SFPQ, FLII, PARP1, and YBX1. We also found that EZH2 interacts 
with a number of RNA binding and processing proteins, including several that are implicated in stem 
cell maintenance such as YBX1 and DDX family proteins [52], suggesting a role for EZH2 in 
translational control. With regard to non-histone enzymatic substrates for EZH2, the identification of 
Figure 4. Structure of eEF1A1 and putative EZH2 methylation target site. (A) Ribbon structure
view of mammalian eEF1A monomer showing close proximity of Lys 55 (highlighted in red) to
the GTP/GDP (Guanosine-5′-tri/diphosphate) binding pocket (with a GDP molecule bound in
the pocket); (B) Hydrophobicity surface view (hydrophobic, red; hydrophilic, blue; neutral, white)
of eEF1A1 showing that K55 is in a hydr philic (blue c lour) region close to GTP/GDP binding pocket
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Table 3. EZH2 interactome lysine methylation hits.
Lys
monomethylation
Protein Name Peptide Sequence PeptideStart Index
Peptide
Stop Index
Variable Modifications
Identified by Spectrum
Methylated
Lys−AtRA
Methylated
Lys +AtRA
CBX3 WKDSDEADLVLAK 142 154 K2: Methyl 12.5% (1/8) ND (0/0)
EZH2 YSQADALKYVGIER 728 741 K8: Methyl 1.5% (2/131) 1.9% (2/106)
Histone H1.2 KASGPPVSELITK 34 46 K1: Methyl 2.1% (2/96) 5% (1/20)
Histone H3.1 KSAPATGGVKPHR 28 41 K10: Methyl 0% (0/18) 16.7% (1/6)
Histone H3.1 EIAQDFKTDLR 74 84 K7: Methyl 5.6% (1/18) 0% (0/6)
MT1X MDPNCSCSPVGSCAC-AGSCKCKECKCTSCK 1 30 K22: Methyl 100% (1/1) ND (0/0)
RL36L KQSGYGGQTKPIFR 44 57 K10: Methyl 33.3% (11/33) 44.4% (8/18)
SUZ12 APQKHGGGGGGGSGPSAGS-GGGGFGGSAAVAAATASGGK 2 40 K4: Methyl 1.3% (2/154) 0% (0/138)
Lys dimethylation
eEF1A1 GSFKYAWVLDK 52 62 K4: Dimethyl 11.9% (7/59) 5.9% (1/17)
eEF1A1 MDSTEPPYSQKR 155 166 K11: Dimethyl 0% (0/59) 5.9% (1/17)
H3.1 KSAPATGGVKKPHR 28 41 K1: Dimethyl 5.6% (1/18) 50% (3/6)
Histone H4 KVLRDNIQGITKPAIR 21 36 K1: Dimethyl 0% (0/86) 4.3% (1/23)
MYO1D SKDTCIVISGESGAGKTEASK 93 113 K2: Dimethyl ND (0/0) 100% (3/3)
RBP56 GPMTGSSGGDRGGFK 196 210 K15: Dimethyl 36.4% (8/22) 0% (0/6)
TR150 DSRPSQAAGDNQGDEAKEQ-TFSGGTSQDTK 186 215 K17: Dimethyl 21.9% (7/32) ND (0/0)
Lys trimethylation
ADT2 QYKGIIDCVVR 50 60 K3: Trimethyl 19.1% (4/21) 7.7% (1/13)
HNRPQ GGNVGGKR 558 565 K7: Trimethyl 25% (1/4) 16.7% (1/6)
MT1X MDPNCSCSPVGSCACAGSC-KCKECKCTSCK 1 30
K20: Trimethyl,
K25: Trimethyl,
K30: Trimethyl
100% (1/1) ND (0/0)
ALYREF ADKMDMSLDDIIK 2 14 K3: Trimethyl 0% (0/27) 5.2% (1/19)
K, methylated lysine; ND, not detected.
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In order to validate candidate EZH2 targets, another pull-down was performed with
a pan-methylated lysine antibody in parallel with the EZH2 IP (data not shown). Although
relatively few proteins (25 proteins that had at least 1.5 times more total peptides than in the IgG
control) were found to co-IP with this antibody (at high confidence thresholds), this experiment
confirmed that eEF1A1 and ADT2 are indeed methylated, suggesting that these two proteins may
be direct EZH2 methylation targets (i.e., they co-IP with EZH2 in at least two experiments, they are
immunoprecipitated with the pan-methyl lysine antibody, and methylation sites were found by mass
spectrometry analysis). Of note, there were six other potential hits from the anti-pan-methylated
antibody pull-down that were also found to co-IP with EZH2 (among the final 145 hits)—three other
ribosomal proteins (RPL24, RPL35, RPS27A), as well as SPTB2, LUC7L3, and SFPQ (a transcriptional
co-repressor). Here, however, mass spectrometry failed to identify specific methylation sites.
Table 4. Summary of potential non-histone EZH2 enzymatic targets.
Protein Name Gene Symbol Methylation Site Protein Function
ADT2 (ADP/ATP Translocase 2) SLC25A5 K52me3 ADP/ATP mitochondrial translocase
CBX3 (Chromobox 3) CBX3 K142me1 Heterochromatin binding
eEF1A1 (Elongation factor 1-α1) EEF1A1 K55me2, K165me2 Regulation of elongation
EZH2 (Enhancer of zeste
homology 2) EZH2 K735
me1 Protein lysine methyltransferase
SUZ12 (Polycomb Repressive
Complex 2 Subunit) SUZ12 K4
me1 Regulation of H3K27 methylation and
gene expression
ALYREF (Aly/REF Export
Factor) ALYREF K4
me3 Chaperone of basic-region leucine
zipper (bZIP) proteins
3. Discussion
In this study, we sought to enhance our understanding of the complex biological roles of the PRC2
complex in AML by analysing the EZH2 interactome (Figure 5). We found that previously established
interactions with PRC2-recruiting proteins such as PHF1, PHF19, LCOR, JARID2, and EPOP are
conserved in HL-60 cells and identified several proteins involved in transcriptional regulation including
ALYREF, SFPQ, FLII, PARP1, and YBX1. We also found that EZH2 interacts with a number of RNA
binding and processing proteins, including several that are implicated in stem cell maintenance
such as YBX1 and DDX family proteins [52], suggesting a role for EZH2 in translational control.
With regard to non-histone enzymatic substrates for EZH2, the identification of specifically methylated
lysine residues and co-IP of the respective proteins with anti-EZH2 and anti-pan methyl lysine
antibodies revealed several potential new targets. Importantly, many of the methylated lysine residues
described in this study have been identified elsewhere [53,54], but without pointing to EZH2 as
a candidate methyltransferase.
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Although the exact biological role of methylation of ribosomal proteins remains poorly
characterised, this post-translational modification is likely significant given that it is conserved in
all three animal kingdoms [55]. It is well-established that both the 60S and the 40S subunits contain
methylated residues and that a number of ribosomal proteins such as RPS2, 3, 9, 10, 12, 14, 25, and 27 as
well as RPL23, 29, and 40 can also be methylated including on lysine residues [55]. Such modifications
have been suggested to affect protein-protein interactions and ribosome assembly, RNA binding or
translation accuracy [55]. In this context, the identification the eEF1A1 translation elongation factor as
a substrate for EZH2 warrants further investigation. eEF1A1 lysine methylation has been described
for several different residues, including K55 observed here [53,54]. Studies of EF-Tu (elongation
factor thermo unstable), an Escherichia coli orthologue of eEF1A1, suggest that this conserved residue
(K56 in E. coli) due to its location in the GTPase switch-1 region may enhance translational accuracy
through attenuating GTP hydrolysis [55]. Given that PRC2 complexes have well-established functions
in transcriptional regulation [56], our finding that EZH2 may be involved in translational control
therefore expands the roles that PRC2 complexes play in the control of gene expression.
To date, therapeutic strategies targeting EZH2 have focused almost exclusively on inhibiting
cofactor binding by the enzyme [18]. Even though effective when activating point mutations in
the SET domain are driving lymphomas [57,58] or in the background of tumours harbouring other
epigenetic perturbations [59], targeting the catalytic activity of EZH2 has thus far failed to elicit
the expected response in a number of other malignancies [60,61]. Given that aberrant eEF1A1
activities have been implicated in a number of cancers [62–64] and the translation machinery represents
an important area of oncology research [65], our findings suggest new possibilities for combinatorial
therapeutic approaches.
4. Methods
4.1. Cell Culture and AtRA Treatment
HL-60 AML cells were cultured in RPMI-1640 (Gibco, Waltham, MA, USA) supplemented
with penicillin (50 units/mL)/streptomycin (50 µg/mL) (Gibco, Waltham, MA, USA) and 10% fetal
calf serum (Sigma-Aldrich, St. Louis, MO, USA). Cells were maintained at 37 ◦C and 5% CO2 in
humidified atmosphere. AtRA was purchased from Sigma and was diluted in 1:1 ethanol and dimethyl
sulfoxide (DMSO).
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4.2. Affinity-Purification and Sample Preparation for Mass Spectrometry
HL-60 cells were centrifuged and washed with phosphate-buffered saline (PBS). Cell lysates
prepared using High-salt Lysis Buffer (20 mM HEPES (4-(2-hydroxyethyl)piperazin-1-ylethanesulfonic
acid) pH 7.9; 1.5 mM MgCl2; 0.3 mM NaCl; 0.2 mM EDTA (ethylenediaminetetraacetic acid);
0.1% Triton X100; 0.1 mM DTT (dithiothreitol); 25% Glycerol). Cell lysates were pre-cleared with
protein A/G magnetic beads (Pierce) and incubated overnight at 4 ◦C with: rabbit polyclonal
anti-EZH2 antibody (Abcam, ab186006, Cambridge, MA, USA); mouse monoclonal anti-EZH2
antibody (Cell Signaling Technology, clone AC22, Danvers, MA, USA); rabbit polyclonal anti-methyl
lysine antibody (Abcam, ab7315); mouse IgG (Abcam, ab37355, Cambridge, MA, USA) or rabbit
IgG (Abcam, ab27478, Cambridge, MA, USA) isotype controls. Samples were then incubated
for 2 h with protein A/G magnetic beads. Bound antibody-protein complexes were washed
three times with Low-salt Lysis Buffer (20 mM HEPES pH 7.9; 1.5 mM MgCl2; 0.1 mM NaCl;
0.2 mM EDTA; 0.1% Triton X100; 0.1 mM DTT, three times with 50 mM TEAB (triethylammonium
bicarbonate), and eluted with 5% formic acid. Any residual formic acid was neutralised with 1 M
TEAB and samples were dried in vacuo. Samples were re-dissolved in 5% acetonitrile/50 mM
TEAB and then reduced with TCEP (tris(2-carboxyethyl)phosphine, 5 mM final concentration).
Free cysteines were alkylated with 2-choloroacetamide (10 mM final concentration). Proteins were
digested with trypsin (Promega, Madison, WI, USA) and quenched with neat formic acid after 4 h.
An aliquot of these solutions was taken for direct analysis by liquid chromatography tandem-mass
spectrometry (LC-MS/MS).
4.3. LC-MS/MS
Reversed phase chromatography was performed using an HP1200 platform (Agilent, Santa
Clara, CA, USA). Peptides were resolved on a 75 µm I.D. 15 cm C18 packed emitter column (3 µm
particle size; Nikkyo Technos, Tokyo, Japan) over 30 min or 60 min using a linear gradient of 96:4 to
50:50 Buffer A:Buffer B [Buffer A (1% acetonitrile/3% dimethyl sulfoxide/0.1% formic acid), Buffer B
(80% acetonitrile/3% dimethyl sulfoxide/0.1% formic acid)] at 250 nL/min. Peptides were ionised
by electrospray ionisation using 1.8 kV applied immediately pre-column via a microtee built into
the nanospray source. Samples were infused into an LTQ Velos Orbitrap mass spectrometer (Thermo
Fisher Scientific, Waltham, MA, USA) directly from the end of the tapered tip silica column (6–8 µm
exit bore). MS/MS data were acquired using data dependent acquisition based on a full Fourier
Transform mass spectrometry (FT-MS) scan (30,000 resolution, inject time set to 500 milliseconds and
Automatic gain control (AGC) set to 1,000,000 with preview mode disabled) and internal lock mass
calibration against the ion 401.922718 m/z. The top 20 most intense precursor ions were fragmented
by collision-induced dissociation and analysed using normal ion trap scans (AGC set to 30,000,
normalised collision energy was set to 35% with an activation time of 10 milliseconds). Precursor
ions with unknown or single charge states were excluded from selection. Peptides were measured
in the orbitrap at 30,000 resolution (automatic gain control—AGC of 1,000,000). Peptides were then
fragmented in the ion trap where they were measured at low resolution (AGC—30,000). Full FT-MS
maximum inject time was 500 milliseconds and normalised collision energy was set to 35% with
an activation time of 10 milliseconds. Wideband activation was used to co-fragment precursor ions
undergoing neutral loss of up to −20 m/z from the parent ion, including loss of water/ammonia.
MS/MS was acquired for selected precursor ions with a single repeat count acquired after 5-s delay
followed by dynamic exclusion with a 10 ppm mass window for 10 s based on a maximal exclusion
list of 500 entries.
4.4. Database Searching
Raw MS/MS data were submitted for database searching using Proteome Discoverer v1.4
and Mascot V2.3. The following Mascot search parameters were used: SwissProt Database,
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SwissProt_040511a (526,969 Sequences); taxonomy filter, Homo sapiens (20,305 sequences); enzyme
specificity, trypsin (KR) 2 missed cleavages; mass tolerance; precursor 5 ppm, fragment 0.60 Da; variable
modifications, acetyl (protein N-term); carbamidomethyl (C); oxidation of methionine pyro-Glu
(peptide N-term Q); phosphorylation (STY); methylation (KR); dimethylation (KR); Trimethylation
(K). MS/MS-based peptide and protein identifications were grouped and validated using Scaffold
v4 (Proteome Software Inc. Portland, OR, USA). Protein identifications were automatically accepted
if they contained at least two unique peptides assigned with at least 95% confidence by Peptide
Prophet [66].
4.5. Data Analysis
All MS runs were merged in Scaffold 4.0 and assigned to two categories—IgG and EZH2
IP (or three categories for the initial analysis: IgG, EZH2 IP, and EZH2 IP in AtRA-treated cells).
Fold change difference compared to IgG control (all IgG samples versus all EZH2 IP samples) were
calculated using total spectra as a relative quantitation method (minimum value was set to 0.1
in case spectra were absent e.g., in IgG controls) and then exclusive spectrum count to eliminate
potential spectra belonging to more than one protein (Table S1) [67]. Fisher’s exact test (with
Benjamini-Hoechberg correction) was run in order to highlight potential hits. For the +/−AtRA
analysis, a less stringent filter of 1.5-fold change over IgG was set and then the ratio of all four
Untreated samples versus all three AtRA samples (two untreated versus two AtRA were matched
biological samples) was compared. Proteins altering their relative abundance by a 2-fold change factor
(either up or down) were also compared in the two matched +/−AtRA runs (in order to avoid false
positive hits that pass the 2-fold change cut off, but have different direction in the two matched runs)
and were finally checked to see if they were present in more than one sample. Hits from the global
EZH2 interactome (all seven EZH2 IP samples versus all IgG controls) were further processed using
the online analysis platform CRAPome [42]. The integrated Significance Analysis of INTeractome
(SAINTexpress [43]) module was implemented to remove common contaminants (IgG selected as
a criterion since the IP were of native non-overexpressed and non-tagged EZH2 protein) and to provide
a relatively stringent confidence filter (score ≥ 0.8) for the probability of the bait-prey interactions.
The resulting list of hits (136 proteins) was then enriched using a published PcG complexome MS data
set [44] and the resulting data were processed, visualised, and analysed using Cytoscape (Cluster maker,
MCODE, ClusterONE, and BinGO) as described previously [68]. USCF Chimera viewer [69] was used
to visualise, process, and annotate the crystal structure of EZH2 (pdb: 5HYN) and eEF1A (pdb:4C0S).
5. Conclusions
In this study, we have generated the first EZH2 interactome in AML using an unbiased
mass spectrometry approach. We identified EZH2 interactions with several ribosomal proteins,
some of which are subject to change upon AtRA-induced myeloid differentiation. Our results strongly
suggest that EZH2 is responsible for eEF1A1 K55 di-methylation, indicating a regulatory role in
translation/mRNA processing that may present therapeutic opportunities.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/7/1440/s1.
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